These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2006804)

  • 41. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
    Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic procedures in gastroesophageal reflux disease].
    Tytgat GN
    Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.
    Marrero JM; de Caestecker JS; Maxwell JD
    Gut; 1994 Apr; 35(4):447-50. PubMed ID: 8174979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In support of "step-up therapy" for gastroesophageal reflux disease.
    Beck IT
    Am J Gastroenterol; 2002 Feb; 97(2):503-4. PubMed ID: 11866309
    [No Abstract]   [Full Text] [Related]  

  • 45. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy.
    Kallal SM; Lee M
    West J Med; 1996 May; 164(5):446-8. PubMed ID: 8686308
    [No Abstract]   [Full Text] [Related]  

  • 47. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.
    Chow WH; Finkle WD; McLaughlin JK; Frankl H; Ziel HK; Fraumeni JF
    JAMA; 1995 Aug; 274(6):474-7. PubMed ID: 7629956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Yoshino T; Shio S; Hayakumo T; Kawai K
    Nihon Rinsho; 2004 Aug; 62(8):1504-9. PubMed ID: 15344541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness].
    Abidin ZU; Ivashkin VT; Sheptulin AA; Trukhmanov AS; Okhlobystin AV
    Klin Med (Mosk); 1999; 77(7):39-42. PubMed ID: 10483164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapy for gastroesophageal reflux disease: more is not necessarily better.
    Metz DC
    Am J Gastroenterol; 2003 Sep; 98(9):1913-5. PubMed ID: 14499765
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
    Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
    Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of famotidine in infants.
    Wenning LA; Murphy MG; James LP; Blumer JL; Marshall JD; Baier J; Scheimann AO; Panebianco DL; Zhong L; Eisenhandler R; Yeh KC; Kearns GL
    Clin Pharmacokinet; 2005; 44(4):395-406. PubMed ID: 15828852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ
    Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can famotidine and omeprazole be combined on a once-daily basis?
    Fändriks L; Lönroth H; Pettersson A; Vakil N
    Scand J Gastroenterol; 2007 Jun; 42(6):689-94. PubMed ID: 17505990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
    Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
    Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medical treatment of gastroesophageal reflux disease: options and priorities.
    Thomson AB
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():14-23. PubMed ID: 1349550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Can preoperative administration of H2 blocker reduce the incidence of postoperative nausea and vomiting (PONV)?].
    Nozaki C; Morioka N; Kinoshita M; Takada M; Ozaki M
    Masui; 2007 Oct; 56(10):1161-4. PubMed ID: 17966618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacological management of gastroesophageal reflux disease.
    Lowe RC; Wolfe MM
    Minerva Gastroenterol Dietol; 2004 Sep; 50(3):227-37. PubMed ID: 15729198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease.
    Tytgat GN
    Dig Surg; 1999; 16(1):1-6. PubMed ID: 9949259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.